STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease

By acquiring CymaBay, Gilead will gain a drug being developed for primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks